Matt. overview company's will operational provide activities. the Thanks, I an of
planned First, the executed its Avid annual successfully shutdown during quarter. maintenance
are While very it it [indiscernible], systems. activity And shutdown the an lower pleased year. period this to our the this another process has of we efficiency different for to completed and the ensure have to for temporary is revenues essential contributed
announced are October, therapy we and launched the newly and company's construction schedule. undergoing the currently final development our manufacturing completed are and within housed on which manufacturing facility These suites, CGT we suites in monitoring qualifications. of performance cell environmental gene world-class As have new
into XXXX it expansion million revenue-generating With completed has have expansion. XXXX And multiyear broad this expansions a capabilities. deployed and of both now completion of approximately of latest the capital technical project, from phases of to $XXX we of Avid all upwards capacity
the Looking that Today, up needs now combined the positioned well and advancing our revenue-generating both meet ahead, to our capacity we are future triple CGT our business. we revenue-generating capacity facilities the mammalian million estimate have to than potential customers to more manufacturing of products. $XXX annually, and bring pre-expansion to of total current
the later contributor phase by in attracting the these service already this have operating our serve we and customers our phase. as well largest with believe increasing off, while facilities work in been the paying new of aligned segment with infrastructure the a we underserved later the the previously expansions currently towards whom to [ costs is major by And business. strategy ] margins, projects has backlog associated as This positioning impacted a demonstrated with strong market Avid weight pharma
in to we and to commercial capacity new capabilities and commercialization, that manufacturing, established the demonstrates growing utilizing beginning a biologics services talent have quality this record When with brand and CGT market. of development and Further, for combine the organization we we thrive to now and the will on decades that projects continue services. experience an onboard we attractive focus of Avid's believe our in are early-stage track [indiscernible] signing
the impacted only all in of the we legacy mammalian Avid the filling steel Not roof the effect of program, benefits single we manufacturing from the manufacturing while of of its improve further completion facility. as the quarter, industry. cessation continue also company's the and with enhance this available margins one This forward, did the it look saw ability in expansion most stainless GMP will this to the of modern high-quality our current small-scale quarter now see company's facilities growing second process a the as Avid capacity. under and And
a we disappointing are all have guidance as combined short [indiscernible] has more to reported to certainly a funding XXXX. net As million. to $XXX result, factors in impacted And the than led first are the to $XXX aware, we business the in has million downturn other term, fiscal with biotech half which the of we a
look position. said, being That forward, as we cash an improved we have
stage second We have early an our seen the during increase signings in quarter.
current late-stage FDA pipeline We with approval. high, one have into completed in our our all backlog at the expansion an and half products our second of has all-time activities already received the
As anticipate the best second X at we represents the which the half look year company's history. more 'XX, of of performance fiscal we half the closely half approximating in revenue year, year
we a now at manufacture. X-year our to mark asset at to approach the the the mammalian of new and transforming include both the development the GMP capacity, we time, in of and business of delighted been completion as As increasing capabilities of end capabilities same Avid year, XXth well the CGMP offering broadening the the process as program what are has modernizing base
Also we retire XX business from and at old reactors, commercial years year, our XXth of markedly back we we as stainless [indiscernible] our during close look manufacturing. the which came where CDMO to
XXXX team calendar have While in pursuit diligently goal. these of challenges, has worked our the
As a XXX XX-year products our more base batches to track capacity an modern clinical manufacturing, enter belt accommodate regulatory which and years we become hope over and calendar late commercial a soon of in a base Avid company operating under programs, and pipeline. with of XXXX, is asset with increasingly biologic commercial commercial our needs customer will we XX than diverse with business a phase record some
bit put we a in look forward the has has the guide work monumental phase, of that team with with behind pursuit as which While year serve. not in our company the a in to new back targets of level I it would high be the this ourselves. to and will one happy this undertake of XXXX the the of development excitement shown one will also and we only to we feel surprise set to much capacity such look not us, future Avid. genuinely be that the me market a at at prospect the that there fortitude start we of looks task blessed wavered And filling I how but continuing not of
today, for now up remarks prepared for my Operator? concludes and call can we This the questions. open
